FLAIR hyperintensity along the brainstem surface in leptomeningeal metastases: a case series and literature review

Koichi Mitsuya 1*, Yoko Nakasu 1,2, Shoichi Deguchi 1, Kensei Shirata 3, Koiku Asakura 3, Kazuaki Nakashima 3, Masahiro Endo 3, Toshiaki Takahashi 4 and Nakamasa Hayashi 1

Abstract

Background: The incidence of leptomeningeal metastasis (LM) is underestimated because of its non-specific signs and the low sensitivity of clinical diagnostic modalities. Cerebrospinal magnetic resonance (MR) imaging with and without contrast enhancement (CE) is a gold standard for the neuroradiological assessment of patients with suspected LM. Previous studies suggested that some LM cases show changes of the brainstem surface on non-contrast MR images without or before the appearance of abnormalities on CE images. We assessed the features of this non-contrast MR finding in a cohort of LM patients in this retrospective single-institution study.

Methods: We reviewed head MR images and clinical data of 142 consecutive patients in whom the final diagnosis was LM.

Results: We found that 11 of these 142 patients (7.7%) with LM had band-like hyperintensity on the brainstem surface on non-enhanced FLAIR images, which looked like bloomy rind on cheese. Three of seven patients who were examined using diffusion-weighted imaging showed restricted diffusion in the corresponding lesion site. The above-mentioned 11 patients included 10 women and 1 man, with a median age of 61 years. All 11 patients had primary lung adenocarcinoma. Seven patients had symptomatic hydrocephalus. Ten patients had EGFR-mutated and one had ALK-rearrangement adenocarcinomas. Before the diagnosis of LM, 10 patients had undergone systemic therapy with EGFR-TKI or pemetrexed, and 1 patient with ALK inhibitor and bevacizumab.

Conclusions: We present a series of patients with bloomy rind sign that is non-enhancing LM reliably detected by FLAIR hyperintensity on the brainstem surface. This finding is rare, but may reflect the spread of cancer cells in both the leptomeningeal membrane and the surface of the brain parenchyma specifically in patients with lung adenocarcinomas. Further study is needed to determine the clinical significance of this sign, and the pathophysiological factors associated with it may be clarified by analyzing serial MR images in a larger cohort of patients treated for LM.

Keywords: Brainstem, Diffusion MRI, FLAIR, Leptomeningeal metastasis, Non-small cell lung cancer, Targeted therapy
Leptomeningeal metastasis (LM) is a complication of malignancy with dissemination of cancer cells to the pia mater, arachnoid membrane, and cerebrospinal fluid (CSF). Regarding the frequency of LM, various findings ranging from 5 to 10% of patients with solid cancers have been reported [1, 2]. The incidence of LM may increase with the longer survival of patients with cancer due to the recent development of effective systemic therapies. However, the prognosis is still poor after the diagnosis of LM. Early detection of leptomeningeal disease may allow an appropriate therapeutic plan to be implemented.

The gold standard for the diagnosis of LM is CSF cytology. In clinical practice, evaluation with gadolinium contrast-enhanced (GdCE) magnetic resonance (MR) imaging is most sensitive, and is often the first diagnostic choice for patients with suspected LM. However, CE-MR imaging yields up to 30% false-negative findings [2]. We therefore need more information from patients without abnormal GdCE-MR images.

A few case reports demonstrated abnormalities in fluid-attenuated inversion recovery (FLAIR) imaging of non-enhancing intracranial metastases including LM [3–10]. In particular, FLAIR hyperintensity in the brainstem surface, looking like a bloomy rind on cheese, was a peculiar finding shown to contribute to the detection of subtle LM in four previous studies [6, 7, 9, 10]. This abnormal finding may reflect both an early stage of cancer spread in the CSF space and also the progression of invasion in the brain surface.

In this study, we retrospectively reviewed MR images of our patients with LM to assess the incidence and the background features of FLAIR hyperintensity non-enhancing lesions on the brainstem surface, and speculate about their pathophysiological mechanism.

Methods

Analysis of the medical records was performed after approval by the Institutional Research Ethics Board of Shizuoka Cancer Center (28-J173–28–1-3). Our ethics board waived the requirement for written informed consent for this retrospective observational study.

After anonymizing the data, we reviewed the neurological records, survival data, corresponding plans of radiotherapy and systemic therapy, images, and independent pathological reports. We reviewed head MR images of 142 consecutive patients in whom the final diagnosis was LM during a period of 16 years (September 2002 to August 2018) (Fig. 1). Bloomy rind sign was picked up by two board-certified oncological neurosurgeons (> 10 years of experience in evaluation of neuro-oncological images). The image findings were visually confirmed by three board-certified radiologists (> 10 years of experience in neuro-imaging).

MR imaging was performed with either a 1.5Tesla or a 3Tesla system (Intera and Achieva dStream, Phillips, Best, Netherlands, or Genesis Signa, GE, IL).

The MR (1.5Tesla) imaging parameters were as follows: (1) FLAIR: TR/TE/TI 11000/100/2800 ms; NEX 2; matrix 304 × 219; thickness 5 mm; gap 0.5 mm; FOV 230 mm; (2) DWI: TR/TE 4000/70 ms; NEX 2; matrix 144 × 144; thickness 5 mm; gap 0.5 mm; b = 0 and 1000 s/mm²; FOV 230 mm; and (3) 3D-gradient echo T1WI: TR/TE 7.2/3.5 ms; FA 15; NEX 1; matrix 256 × 256; thickness 4 mm; gap −2 mm; FOV 230 mm.

The MR (3Tesla) imaging parameters were as follows: (1) FLAIR: TR/TE/TI 1100/125/2800 ms; NEX 1; matrix 400 × 235; thickness 5 mm; gap 0.5 mm; FOV 230 mm; (2) DWI: TR/TE 5000/60 ms; NEX 2; matrix 160 × 160; thickness 5 mm; gap 0.5 mm; b = 0 and 1000 s/mm²; FOV 230 mm; and (3) 3D-gradient echo T1WI: TR/TE
4.0/1.8 ms; FA 12; NEX 1; matrix 240 × 396; thickness 4 mm; gap – 2 mm; FOV 230 mm.

As contrast medium, meglumine gadopentetate (0.2 ml/kg) was used until October 2015 and gadobutrol (0.1 ml/kg) since November 2015.

Final diagnosis of LM was given by neurological examination, CSF cytology or radiographic evaluation according to RANO response criteria for LM [11]. CSF cytology was positive in 104 cases.

Results

We found that 13 of 142 patients (9.2%) with LM had band-like FLAIR hyperintensity on the brainstem surface. Eleven (7.7% of the total) of these 13 patients had none or only faint abnormalities of the lesions on GdCE MR images, whereas the two other patients were excluded because of definitely abnormal enhancement of the leptomeninges: one patient with cancer of unknown origin and the other with breast cancer (Fig. 1). The age of the 11 patients ranged from 46 to 72 years (median 61 years), and there were 10 women and 1 man. Definitive diagnosis was made by cytological examination of CSF in all patients except one. Nine patients (9/11 = 81.8%) had symptomatic hydrocephalus that needed CSF shunt surgery (Table 1).

All 11 patients had primary lung adenocarcinoma. Ten patients had epidermal growth factor receptor (EGFR)-mutated and one had anaplastic lymphoma kinase (ALK)-rearrangement adenocarcinomas. Before the diagnosis of LM, ten patients had undergone systemic therapy with EGFR-tyrosine kinase inhibitor (TKI) or pemetrexed, and the patient with ALK rearrangement had undergone treatment with systemic ALK inhibitor and bevacizumab (Table 1).

FLAIR images showed a hyperintense band along the anterior and lateral surfaces of the brainstem extending to the cerebellar peduncle, even to the walls of the fourth ventricle. It was a clear and dense layer on the surface of the brainstem looking like a bloomy rind on cheese, symmetrical in all 11 cases, and had some accentuation or interruption (Fig. 2). Overall, 6 of the 11 cases (54.5%) showed no abnormal enhancement of the brainstem, but five had only subtle enhancement on part of the lesion on GdCE MR images. Diffusion-weighted (DW) imaging was performed for 7 of the 11 patients and demonstrated the surface lesions as having restricted diffusion in 3 patients and normal in 4 of them (Table 1).

In this study, 10 of 11 patients had positive CSF cytology, and remaining one did not undergo CSF cytological examination because of definitive neurological sings and MR findings. From another point of view, CSF cytology was positive in 104 patients:10 patients showed both positive CSF cytology and bloomy rind sign, however, 94 patients showed positive CSF cytology but no bloomy rind sign.

All 11 patients had received systemic therapy for lung cancer before the diagnosis of LM with bloomy rind sign: 9 with an EGFR-TKI, one with an EGFR-TKI plus an anti-angiogenic antibody, and another with cytotoxic anti-cancer drugs plus an anti-angiogenic antibody (Table 1).

| Table 1 | Patient characteristics |
|---------|-------------------------|
| Patients | 11 |
| Median age (range) years | 60 (46–72) |
| Gender | |
| Male | 1 (9) |
| Female | 10 (91) |
| Primary cancer | |
| Lung adenocarcinoma | 11 (100) |
| Driver mutation | |
| EGFR mutant | 10 (91) |
| 19 del | 5 |
| 21L858R | 4 |
| NA (NoSmokFem, supposed to be positive) | 1 |
| ALK rearrangement | 1 (9) |
| Area of FLAIR hyperintensity (Bloomy Rind Sign) | |
| Pons | 9 (82) |
| Midbrain and pons | 1 (9) |
| Pons and medulla | 1 (9) |
| GdCE T1W images at the same lesion | |
| No abnormality | 6 (55) |
| Subtle abnormality | 5 (45) |
| DW images at the same lesion | |
| Restricted diffusion | 3 (27.2) |
| No abnormality | 4 (36.4) |
| NA | 4 (36.4) |
| Treatment regimen before LM | |
| Gefitinib | 3 (27.25) |
| Gefitinib, Pemetrexed+/−Pratium | 3 (27.25) |
| Erlotinib, Gefitinib, Pemetrexed | 1 (9) |
| Erlotinib, Pratium+Pemetrexed, Taxane | 1 (9) |
| Osimertinib | 1 (9) |
| Pratium+Taxane+Bevacizumab, Pemetrexed | 1 (9) |
| Alectinib, Pratium+Taxane+Bevacizumab | 1 (9) |
| Symptomatic hydrocephalus | |
| Yes | 7 (64) |
| No | 4 (36) |
| Brain parenchymal metastasis | |
| Yes | 9 (82) |
| No | 2 (18) |

NA Not available
Representative case
A woman was diagnosed with lung adenocarcinoma and underwent chemotherapy with gefitinib. She was admitted to our hospital with headache and nausea. Brain MR images showed a hyperintense lesion along the brainstem surface on FLAIR and DW images (Fig. 3a). There were no enhancing lesions with GdCE in the brain parenchyma or leptomeninges. Cytological examination of lumbar spinal fluid revealed malignant cells. She underwent lumbar-peritoneal shunt surgery followed by whole-brain radiation...
therapy, which improved her symptoms. Brain MR images demonstrated disappearance of the hyperintense lesion on FLAIR at this stage (Fig. 3b). However, 2 months later, she was admitted with deteriorated neurological symptoms. Brain MR images showed a non-enhancing, FLAIR hyperintensity lesion along the brainstem surface again (Fig. 3c).

Discussion
LM may increase in incidence with the longer survival of patients with solid cancer due to the development of effective systemic therapies. However, the prognosis is still poor after the diagnosis of LM, and individualized treatment have not been established. Early detection of LM by non-invasive measures would enhance optimal clinical approaches to this devastating disease. In this retrospective study, we demonstrated that FLAIR imaging as a potentially simple method for early detection of LM specifically in patients with non-small cell lung cancer (NSCLC).

FLAIR hyperintensity on the brainstem surface without abnormal enhancement is a characteristic but rare finding as we retrospectively identified it in only 11 (7.7%) of 142 patients with known LM at our institute. We called this characteristic layer of hyperintensity a bloomy rind sign. All patients had LM from lung adenocarcinoma, they had undergone chemotherapy mainly with TKIs, and five patients had also undergone whole-brain radiotherapy before presenting LM.

Reviewing the literature, we identified nine cases with similar MR findings, all of which had lung adenocarcinoma [6, 7, 9, 10]. The clinical characteristics of the nine cases are summarized in Table 2. There were five males, one female, and three others of unknown sex, with ages ranging from 39 to 77 years. All of the cases had NSCLC as well as our 11 cases. Seven cases had bone, lung, or brain parenchymal metastasis. Six cases had confirmed EGFR gene mutations and the other three cases had not undergone mutational analysis. In one patient, the FLAIR hyperintensity of the brainstem led to the diagnosis of primary lung cancer [9]. Five cases had taken an EGFR-TKI before diagnosis of the LM. Five cases had malignant cells in CSF and three others were associated with brain parenchymal metastasis. The brain lesions were treated with radiotherapy in three cases, intrathecal chemotherapy in one, and EGFR-TKIs in three.

For detecting LM, FLAIR images reportedly had a specificity as high as GdCE T1-weighted images, although they had low sensitivity [12, 13]. For the detection of non-enhancing LM, FLAIR hyperintensity of the brainstem surface may contribute to the diagnosis of patients as a non-invasive diagnostic measure. As for a definitive

| Case | Author, publish year | Age | Sex | Primary cancer | EGFR mutation | Systemic metastasis | Chemotherapy agents used before LM | CSF cytology | Treatment for LM | Prognosis |
|------|----------------------|-----|-----|----------------|---------------|---------------------|-------------------------------------|--------------|------------------|-----------|
| 1    | Crombe, 2014 [6]     | 56  | M   | Lung adenocarcinoma | Positive     | Bone, Lung | gefitinib | Malignant cells | NA         | 2 M (Respilatory fail) |
| 2    | Khil et al. 2015 [7] | 75  | M   | Lung adenocarcinoma | NA, but supposed to be positive*1 | Bone | gefitinib | Malignant cells | NA         | 1 M (Respilatory fail) |
| 3    | Khil et al. 2015 [7] | 47  | F   | Lung adenocarcinoma | NA | Brain | CBDCA+PTX | NA | WBRT | Hospice care |
| 4    | Cheng, 2017 [9]      | 39  | M   | Lung adenocarcinoma | Positive (19 del) | Lung | CDDP+VNR, gefitinib | Malignant cells | IT-lg, steroid, IT-CTX, and erlotinib | 1Y (Sepsis) |
| 5    | Cheng, 2017 [9]      | NA  | NA  | Lung adenocarcinoma | Positive | Brain, Lung | CDDP+VNR, gefitinib | NA | WBRT | Lost to follow up |
| 6    | Cheng, 2017 [9]      | NA  | NA  | Lung adenocarcinoma | Positive (21 L858R) | Bone, Lung | none | negative gefitinib, afatinib | NA         | 7 M (Respilatory fail) |
| 7    | Cheng, 2017 [9]      | NA  | NA  | Lung adenocarcinoma | Positive (19 del, T790M) | Bone, Brain, Lung | erlotinib, VNR, pemetrexed, and gemcitabine | NA | WBRT, osimertinib | survival over 6 M |
| 8    | Maeda, 2019 [10]     | 55  | M   | Lung adenocarcinoma | Positive (19 del) | NA | NA | Malignant cells | NA | spread to medulla after 4 M |
| 9    | Maeda, 2019 [10]     | 77  | M   | Lung adenocarcinoma | NA | NA | NA | Malignant cells | NA | |

*1. The author did not mention if there was EGFR mutation, but the patient received gefitinib
NA Not available; CBDCA Carboplatin; CDDP Cisplatin; VNR Vinorelbine; WBRT Whole brain radiotherapy; IT Intratheral; CTx Chemotherapy; Ig Immunoglobulin
PTX Paclitaxel

Table 2 Previous reports of FLAIR hyperintensity on the brainstem surface without abnormal enhancement (Bloomy rind sign)
diagnosis, non-enhancing images may need to be improved in terms of their sensitivity and used in combination with other diagnostic tools.

Although the mechanism behind the FLAIR hyperintensity of the brainstem surface without abnormal enhancement in LM remains unclear, the results of our study provide information for understanding the pathophysiology of this disease. First, T1-weighted MR imaging may have a limitation in terms of its spatial resolution for detecting subtle enhancement of thin layers along the brainstem surface [8]. Disturbances in the blood-brain or blood-CSF barrier and vascularization may vary in degree and distribution on the thin surface around the brainstem. Second, our study showed restricted diffusion in three of seven patients examined by DW imaging. That may reflect cytotoxic edema involving the brainstem surface, and may also reflect microinfarction due to vascular injury by invaded tumor cells [5, 7]. Third, the restricted diffusion may also be caused by highly cellular infiltrating cancer in the subarachnoid and subpial spaces of the brainstem [9]. Fourth, targeted therapy may result in the regression of microvessels and inhibition of neovascularization, leading to less of an enhancement effect of active cancer on MR images [4, 8, 14]. Fifth, the findings in seven patients harboring hydrocephalus in our study suggested retention of CSF in isolated subarachnoid spaces and infiltration into the brainstem surface. One patient had severe hydrocephalus and her abnormal FLAIR hyperintensity was reversible in accordance with her good clinical response to lumbar-peritoneal CSF shunt surgery (Fig. 3).

Increasing use of anti-angiogenic and immune-modulating drugs for systemic cancers may modify the diagnostic sensitivity of MR images with GdCE T1-weighted imaging. Closer examination with FLAIR and DW images may support early detection of the devastating disease of LM.

**Limitations**

Although unenhanced FLAIR images reportedly have sufficient specificity for detecting LM [13], we have to carefully interpret the leptomeningeal hyperintensity and differentiate LM from other pathological conditions such as subarachnoid hemorrhage, bacterial meningitis, and low intracranial pressure. Other limitations in this retrospective study include that the number of cases was limited and that MR imaging was performed using different instruments and sequences. In addition, DW imaging was performed only in selected patients. We need more information of this rare and subtle abnormality with better resolution. Finally, patients with LM were not sufficiently followed up with frequent MR imaging in their courses of difficult treatment.

**Conclusions**

In this paper, we have presented a series of patients with non-enhancing LM that was detected by FLAIR hyperintensity on the brainstem surface. This bloomy rind sign is rare, but may reflect both the early stage of LM and progressive infiltration into the brain surface. Non-contrast sequences should be carefully examined when evaluating LM in patients with NSCLC, especially those with a history of TKI therapy. The mechanism behind this sign remains unclear, but we hypothesized that it involves various pathological processes. Further study is needed to determine the clinical significance of this sign and the factors correlated with it. Prospective analysis of serial MR images in patients with LM from NSCLC may provide clues to understand the mechanism and to improve the available therapeutic options.

**Abbreviations**

ALK: Anaplastic lymphoma kinase; CSF: Cerebrospinal fluid; DW: Diffusion-weighted; EGFR: Epidermal growth factor receptor; FLAIR: Fluid-attenuated inversion recovery; GdCE: Gadolinium contrast enhancement; LM: Leptomeningeal metastasis; MR: Magnetic resonance; NSCLC: Non-small cell lung cancer; TKI: Tyrosine kinase inhibitor

**Acknowledgements**

Not applicable.

**Authors’ contributions**

KM designed the study with YN. KM, SD, KS, KA, ME, and TT collected data. KM, SD, KN and NH gathered clinical data and performed analysis. KM and YN interpreted results, and prepared and drafted the manuscript. All authors read and approved the final manuscript.

**Funding**

This work has not been funded.

**Availability of data and materials**

No additional data.

**Ethics approval and consent to participate**

Approval for this study was obtained from ethical review board of Shizuoka Cancer Center. Individual written informed consent was waived because this study was retrospective in design and based on database extracted records. The waivers of participant consent were approved by the ethical review boards of Shizuoka Cancer Center.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 Division of Neurosurgery, Shizuoka Cancer Center, Nagaizumi, Shizuoka 4118777, Japan. 2 Division of Neurosurgery, Shiga University of Medical Science, Otsu, Shiga, Japan. 3 Division of Diagnostic Radiology, Shizuoka Cancer Center, Nagaizumi, Shizuoka, Japan. 4 Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Shizuoka, Japan.

**Received:** 28 June 2020  **Accepted:** 11 November 2020

**Published online:** 23 November 2020

**References**

1. Groves MD. Leptomeningeal disease. Neurosurg Clin N Am. 2011;22:67–78.
2. Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Rudà R,
Preusser M. EANO executive board and ESMO guidelines committee: EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017;28(suppl 4):iv84–99.

3. Lee JH, Na DG, Choi KH, Kim KJ, Ryoo JW, Lee SY, Suh YL. Subcortical low intensity on MR images of meningitis, viral encephalitis, and leptomeningeal metastasis. AJNR Am J Neuroradiol. 2002;23:535–42.

4. Karimi S, Lis E, Gilani S, D’Ambrosio N, Holodny A. Nonenhancing brain metastases. J Neuromaging. 2011;21:184–7.

5. Ayzenberg I, Börnke C, Tönnes C, Ziebarth W, Lavrov A, Lukas C. Extensive cortical involvement in leptomeningeal carcinomatosis. J Clin Neurosci. 2012;19:173–5.

6. Crombe A, Alberti N, Durieux M, Frullo N, Douset V, Toudias T. Exceptional symmetric anterior brainstem involvement in leptomeningeal carcinomatosis. J Neuroradiol. 2014;41:279–81.

7. Khil EK, Lee AL, Chang KH, Yun TJ, Hong HS. Symmetrical curvilinear cytotoxic edema along the surface of the brainstem: A probable new magnetic resonance imaging finding of leptomeningeal carcinomatosis. Medicine (Baltimore). 2015;94:e1053.

8. Hatzoglou V, Karimi S, Diamond EL, Lis E, Krol G, Holodny AI, Young RJ. Nonenhancing leptomeningeal metastases: imaging characteristics and potential causative factors. Neurohospitalist. 2016;6:24–8.

9. Cheng CY, Hsu CY, Tsai YH, Lin KL, Huang CE, Fan YH, Chin SC, Huang YC. Novel anterior brainstem magnetic resonance imaging findings in non-small cell lung cancer with leptomeningeal carcinomatosis. Front Neurol. 2017;8:579.

10. Maeda K, Wada H, Ozaki Y, Inoue A. Symmetric ventral brainstem lesion in leptomeningeal carcinomatosis. Intern Med. 2019;58:759–60.

11. Chamberlain M, Junick L, Brandsma D, Soffetti R, Rudà R, Raizer J, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Walker J, van den Bent M, Wen PY, Jaeckle KA. Leptomeningeal metastases: a RANO proposal for response criteria. Neuro-Oncology. 2017;19:484–92.

12. Singh SK, Agris JM, Leeds NE, Ginsberg LE. Intracranial leptomeningeal metastases: comparison of depiction at FLAIR and contrast-enhanced MR imaging. Radiology. 2000;217:50–3.

13. Singh SK, Leeds NE, Ginsberg LE. MR imaging of leptomeningeal metastases: comparison of three sequences. AJNR Am J Neuroradiol. 2002;23:817–21.

14. Kleinschmidt-DeMasters BK, Damek DM. The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis. J Neuro-Oncol. 2010;96:375–84.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions